Relmada Therapeutics (RLMD) Misses Q3 EPS by 4c

Relmada Therapeutics (NASDAQ: RLMD) reported Q3 EPS of ($0.72), $0.04 worse than the analyst estimate of ($0.68).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• UBS says bull market has further to run
• Crypto stocks continue rallying as Bitcoin extends gains on regulation push
• Global yield relief evaporates as U.S. rates push back toward multi-decade peaks